Paul Sagan | Investor Relations |
Glenn Mattes | President and Chief Executive Officer |
Kirk Coleman | Chief Financial Officer |
Chris Cano | Vice President-Business Development |
Bill Williams | University of Texas, Austin |
Jonathan Aschoff | ROTH Capital Partners |
Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals’ Second Quarter 2020 Financial Results Conference Call.
As a reminder, this conference call is being recorded. I would now like to turn the call over to your host, Mr. Paul Sagan of TFF Pharmaceuticals, Investor Relations.
You may begin your conference.